key: cord-0929833-g4yo4df2
authors: Qiao, Jialu; Li, Weiling; Bao, Jian; Peng, Qian; Wen, Dongmei; Wang, Jianing; Sun, Binlian
title: The expression of SARS-CoV-2 receptor ACE2 and CD147, and protease TMPRSS2 in human and mouse brain cells and mouse brain tissues
date: 2020-09-14
journal: Biochem Biophys Res Commun
DOI: 10.1016/j.bbrc.2020.09.042
sha: 010ae38db96bbbafdc3e6d4d39c9d863d788b504
doc_id: 929833
cord_uid: g4yo4df2

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been discovered as the pathogenic cause of the coronavirus disease 19 (COVID-19). Cellular entry of SARS-CoV-2 are mediated by the spike glycoprotein of virus, and the host specific receptors and proteases. Recently, besides pulmonary complications as the chief symptom, investigations have also revealed that SARS-CoV-2 can trigger neurological manifestations. Herein, to investigate the expression level of receptors and related proteases is important for understanding the neuropathy in COVID-19. We determined the expression levels of receptor ACE2 and CD147, and serine protease TMPRSS2 in human and mouse brain cell lines and mouse different region of brain tissues with qRT-PCR and Western blot. The results showed that the expression pattern of all them was very different to that of lung. ACE2 is lower but CD147 is higher expressed in mostly brain cell lines and mouse brain tissues comparing with lung cell line and tissue, and TMPRSS2 has consistent expression in brain cell lines and mouse lung tissues. It is suggested that SARS-CoV-2 might have a different way of infection to cerebral nervous system. Our finding will offer the clues to predict the possibility of SARS-CoV-2 infection to human brain nervous system and pathogenicity.

pattern of all them was very different to that of lung. ACE2 is lower but CD147 is 37 higher expressed in mostly brain cell lines and mouse brain tissues comparing with 38 lung cell line and tissue, and TMPRSS2 has consistent expression in brain cell lines 39 and mouse lung tissues. It is suggested that SARS-CoV-2 might have a different way 40 of infection to cerebral nervous system. Our finding will offer the clues to predict the 41 possibility of SARS-CoV-2 infection to human brain nervous system and dry cough and headache and so on [1] . It is reported that SARS-CoV-2 injures not just SARS-CoV-2 is still unknown.

The presence of receptors is a necessary condition for virus to enter target cells.

Although the detail mechanism is not clear, it is reported that angiotensin-converting 58 enzyme 2 (ACE2) and/or CD147 is the important receptor for virus binding to cells, 59 and the transmembrane protease serine 2 (TMPRSS2) is important for virus entry into Moreover, the recent experimental and clinical findings suggest that CD147 might 68 also act as a receptor mediating SARS-CoV-2 entry through binding to S protein.

CD147 is a type II transmembrane glycoprotein that belongs to the immunoglobulin 70 superfamily and plays a significant role in intercellular recognition in immunology 71 and cellular differentiation [4] , and is a widely expressed protein in many cell types 

The obtained cDNAs were used as templates for quantitative real-time PCR 117 (qRT-PCR) amplification to determine the mRNA expression levels of ACE2, CD147 118 and TMPRSS2 with specific primers (Table 1) using TB GreenPremix Ex Taq (Takara 119 Bio, Inc., Otsu, Japan). The housekeeping GAPDH gene was used for normalization.

The relative expression levels (2 -ΔΔCt ) of different cell lines and mouse tissues were 121 compared with that of Calu3 cells and mouse lung tissue respectively. significantly weak in brain cell lines comparing with Calu3 cell (Fig.1A) . Similar to 152 mRNA, the protein of ACE2 was almost not expressed in human brain cell lines, but 153 showed higher expression in Calu3 cell (Fig.1D) . However, there was a higher mRNA 154 level of CD147 in brain cell lines compared with Calu3 cell (Fig.1B) . SY5Y showed 155 significant higher CD147 protein level than that in Calu3, while HMC3 showed 156 similar level (Fig.1D) . Protein CD147 in U87 could hardly be detected although its and protein, and lower level of them in U87 (Fig.1C&D) . These results might suggest 162 that SARS-CoV-2 had a different way of infection to brain cells compared with the 163 lung cells. 164 We also determined the mRNA level and protein level of ACE2, CD147 and 165 TMPRSS2 in different region of mouse brain tissues, and mouse brain cell lines 166 neuroblastoma cells N2a and microglial cells BV2. Similar to human brain cell lines, 167 the results showed that the mRNA of ACE2 in almost all regions of mouse brain and 168 cell lines were lower than that in lung tissue except Hypophysis, and both mRNA and 169 protein level of ACE2 in Hypophysis showed higher levels comparing to other region 170 of brain tissues. Cortex showed higher protein level of ACE2 but lower mRNA level 171 (Fig.2A&D) . Interesting, consistent mRNA of CD147 could be found in all tested 172 tissues and cells, especially in Hypophysis it is more than 5 times of that in lung 173 (Fig.2B ). Moreover, all tested brain tissues and cells showed significant higher 174 CD147 protein levels than that in lung (Fig.2D) . There was high expression of 175 TMPRSS2 mRNA in mouse Cortex, Hypophysis and Cerebellum among the tested 176 tissues, but not in Corpus striatum, N2a and BV2 cells (Fig.2C ). In addition, besides 

In this study, we detected the expressions of SARS-CoV-2 receptor ACE2, CD147 184 and serine protease TMPRSS2 in human and mouse brain cell lines, also in mouse ataxia, impaired consciousness and other neurological diseases. Therefore, the 208 susceptibility of these brain regions to SARS-CoV-2 may be one of the reasons for the 209 cognitive and neurological impairment in patients. Moreover, it was reported that S 210 protein of SARS-CoV-2 had lower affinity with CD147 than ACE2 [4] , which may 211 explain the low direct infectivity of SARS-CoV-2 to brain. All of these implied that 

Clinical Characteristics of 138 Hospitalized Patients With

Potential neuroinvasive pathways of SARS-CoV-2: Deciphering the 240 spectrum of neurological deficit seen in coronavirus disease-2019 (COVID-19)

SARS-CoV-2 Cell Entry Depends on ACE2 243 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 invades host cells via a novel route: 245 CD147-spike protein

Cell entry mechanisms of SARS-CoV-2, Proc Natl Acad Sci U S diagnosed with coronavirus disease

Neurologic Manifestations of Hospitalized Patients With 261

Coronavirus Disease

National Health Commission of the People′s Republic of China. Diagnosis and treatment of the 263 novel coronavirus pneumonia

Human Coronaviruses and Other Respiratory 265 Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System?

Detection of SARS coronavirus RNA in the cerebrospinal 267 fluid of a patient with severe acute respiratory syndrome

Middle East Respiratory Syndrome

The protein expression profile of ACE2 in human tissues

A genome-wide transcriptomic analysis of 273 protein-coding genes in human blood cells

Transcriptomics resources of human tissues and 275 organs

Deep sequencing of the murine olfactory receptor 277 neuron transcriptome

Hierarchical deconstruction of mouse olfactory 279 sensory neurons: from whole mucosa to single-cell RNA-seq

 227 We would like to thank Kuan Lin and Xiaokang Gong for technical support. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Please note that all Biochemical and Biophysical Research Communications authors are required to report the following potential conflicts of interest with each submission. If applicable to your manuscript, please provide the necessary declaration in the box above.(1) All third-party financial support for the work in the submitted manuscript.(2) All financial relationships with any entities that could be viewed as relevant to the general area of the submitted manuscript.(3) All sources of revenue with relevance to the submitted work who made payments to you, or to your institution on your behalf, in the 36 months prior to submission. (4) Any other interactions with the sponsor of outside of the submitted work should also be reported. (5) Any relevant patents or copyrights (planned, pending, or issued). (6) Any other relationships or affiliations that may be perceived by readers to have influenced, or give the appearance of potentially influencing, what you wrote in the submitted work. As a general guideline, it is usually better to disclose a relationship than not.